CMC Biopharmaceuticals forecasts its first operating profit in 2006  

2006.12.07
The Danish contract manufacturing company has increased its revenues by 50% in 2006 and forecasts its first profit this year
CMC Biopharmaceuticals A/S (CMC), a contract manufacturing company located in Copenhagen, has increased its revenues by 50% in 2006 and forecasts its first profit this year. David Kaufmann, chairman of the board of CMC says: "We expect to come out with a positive result this year. If you take earnings minus interest and tax, then it is very positive."
 
CMC offers manufacturing services using microbial fermentation and mammalian cell culture processes including process development and scale-up of protein processes, and production of biopharmaceuticals for pre-clinical and clinical trials.
 
According to Jesper Zeuthen, director of biotech investments of BankInvest, CMC is a new type of company in Denmark. "There is no other company in the country which can do anything similar. In that sense they are quite unique," says Zeuthen.
 
Customers of CMC come mainly from abroad and the Danish firm currently has contracts with 15 pharmaceutical companies. The news was reported by professional journal Ingeniøren (The Engineer).
 
Link > CMC 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×